Rhumbline Advisers Cara Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024
SELL
$0.24 - $0.92 $11,097 - $42,541
-46,241 Reduced 60.12%
30,677 $7,000
Q1 2024

May 09, 2024
BUY
$0.52 - $1.05 $1,640 - $3,312
3,155 Added 4.28%
76,918 $69,000
Q4 2023

Feb 08, 2024
SELL
$0.6 - $1.65 $1,296 - $3,564
-2,160 Reduced 2.84%
73,763 $54,000
Q3 2023

Nov 09, 2023
SELL
$1.67 - $3.33 $1,187 - $2,367
-711 Reduced 0.93%
75,923 $127,000
Q2 2023

Aug 08, 2023
SELL
$2.83 - $4.94 $221,257 - $386,224
-78,183 Reduced 50.5%
76,634 $216,000
Q1 2023

May 11, 2023
BUY
$4.89 - $12.27 $41,232 - $103,460
8,432 Added 5.76%
154,817 $760,000
Q4 2022

Feb 14, 2023
BUY
$8.88 - $12.77 $9,430 - $13,561
1,062 Added 0.73%
146,385 $1.57 Million
Q3 2022

Nov 10, 2022
BUY
$8.24 - $12.56 $73,303 - $111,733
8,896 Added 6.52%
145,323 $1.36 Million
Q2 2022

Aug 11, 2022
BUY
$7.45 - $13.84 $48,052 - $89,268
6,450 Added 4.96%
136,427 $1.25 Million
Q1 2022

May 12, 2022
BUY
$9.94 - $12.65 $874 - $1,113
88 Added 0.07%
129,977 $1.58 Million
Q4 2021

Feb 10, 2022
SELL
$11.99 - $18.14 $12,289 - $18,593
-1,025 Reduced 0.78%
129,889 $1.58 Million
Q3 2021

Nov 12, 2021
SELL
$11.55 - $16.06 $206,675 - $287,377
-17,894 Reduced 12.02%
130,914 $2.02 Million
Q2 2021

Aug 05, 2021
BUY
$12.38 - $29.19 $1.18 Million - $2.78 Million
95,239 Added 177.79%
148,808 $2.12 Million
Q1 2021

May 06, 2021
SELL
$15.07 - $21.71 $52,247 - $75,268
-3,467 Reduced 6.08%
53,569 $1.16 Million
Q4 2020

Feb 10, 2021
BUY
$12.72 - $16.16 $27,475 - $34,905
2,160 Added 3.94%
57,036 $863,000
Q3 2020

Nov 12, 2020
SELL
$12.34 - $17.92 $102,014 - $148,144
-8,267 Reduced 13.09%
54,876 $698,000
Q2 2020

Aug 13, 2020
BUY
$12.39 - $17.33 $53,958 - $75,472
4,355 Added 7.41%
63,143 $1.08 Million
Q1 2020

May 06, 2020
SELL
$9.12 - $17.78 $21,769 - $42,440
-2,387 Reduced 3.9%
58,788 $777,000
Q4 2019

Feb 05, 2020
BUY
$16.11 - $25.98 $79,518 - $128,237
4,936 Added 8.78%
61,175 $986,000
Q3 2019

Oct 23, 2019
BUY
$18.28 - $26.91 $95,659 - $140,820
5,233 Added 10.26%
56,239 $1.03 Million
Q2 2019

Aug 14, 2019
BUY
$17.68 - $21.57 $78,958 - $96,331
4,466 Added 9.6%
51,006 $1.1 Million
Q1 2019

May 01, 2019
BUY
$14.41 - $19.64 $35,563 - $48,471
2,468 Added 5.6%
46,540 $913,000
Q4 2018

Jan 31, 2019
BUY
$12.45 - $23.47 $199,000 - $375,144
15,984 Added 56.91%
44,072 $573,000
Q3 2018

Nov 07, 2018
BUY
$17.57 - $23.95 $25,089 - $34,200
1,428 Added 5.36%
28,088 $673,000
Q2 2018

Aug 06, 2018
BUY
$11.6 - $19.27 $15,706 - $26,091
1,354 Added 5.35%
26,660 $511,000
Q1 2018

May 02, 2018
SELL
$11.77 - $16.08 $9,474 - $12,944
-805 Reduced 3.08%
25,306 $313,000
Q4 2017

Feb 09, 2018
SELL
$11.86 - $14.08 $58,007 - $68,865
-4,891 Reduced 15.78%
26,111 $320,000
Q3 2017

Nov 06, 2017
BUY
$12.6 - $16.34 $390,625 - $506,572
31,002
31,002 $424,000

Others Institutions Holding CARA

# of Institutions
74
Shares Held
12.8M
Call Options Held
0
Put Options Held
0
View Full List

About Cara Therapeutics, Inc.

CARA Quotes by TradingView
  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $278M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email